<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR1800014623</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2018-01-24</date_registration>
      <primary_sponsor>Tongji Hospital of Tongji University </primary_sponsor>
      <public_title>A prospective study on therapeutic effect of Mesenchymal stem cell on patients with primary Sjogren Syndrome</public_title>
      <acronym />
      <scientific_title>A prospective study on therapeutic effect of Mesenchymal stem cell on patients with primary Sjogren Syndrome</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2018-02-01</date_enrolment>
      <type_enrolment />
      <target_size>stem cell group:20;hydroxychloroquine group:20;</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=24947</url>
      <study_type>Interventional study</study_type>
      <study_design>Randomized parallel controlled trial</study_design>
      <phase>New Treatment Measure Clinical Study</phase>
      <hc_freetext>Sjogren Syndrome</hc_freetext>
      <i_freetext>stem cell group: Intravenous use mesenchymal stem cell ;hydroxychloroquine group:oral use hydroxychloroquine ;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Xuan Wang</firstname>
        <middlename />
        <lastname />
        <address>389 Xincun Road, Putuo District, Shanghai, China</address>
        <city />
        <country1 />
        <zip>200065</zip>
        <telephone>+86 13918745569</telephone>
        <email>baroquewang@icloud.com</email>
        <affiliation>Tongji Hospital of Tongji University</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Jianping Tang</firstname>
        <middlename />
        <lastname />
        <address>389 Xincun Road, Putuo District, Shanghai, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 18964869005</telephone>
        <email>tangjp6512@126.com</email>
        <affiliation>Tongji Hospital of Tongji University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>(1) According to 2002 International Classification Standard for Sjogren syndrome;
(2) informed consent signed;approved by Ethics Committee of Tongji hospital;
(3) aged from 18 to 65 years old, male or female;
(4) ESSDAIâ‰¥4.
At least 1 of the following 3 items:
(5) refractory immune Leukopenia or thrombocytopenia;
(6) interstitial lung disease;
(7) cannot be healed by conventional immunosuppressive therapy.</inclusion_criteria>
      <agemin />
      <agemax />
      <gender>Both</gender>
      <exclusion_criteria>(1) patient In remission;
(2) severe organ dysfunction(heart/lung/liver/kidney);
(3) combined with systemic infection or severe focal infection;
(4) a variety of drug allergies;
(5) breast-feeding and pregnant women.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>ESSDAI;immunoglobulin;complement;thrombocyte;leukocyte;pulmonary CT;salivary flow rate;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>antinuclear antibodies;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Fund of Tongji hospital</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Not approved</status>
        <approval_date>2013-08-26</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>